Bristol Myers Squibb announced the first disclosure of data from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo co-formulated with Halozyme’s proprietary recombinant human hyaluronidase compared to intravenous Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma who have received prior systemic therapy, demonstrating noninferiority for the co-primary endpoints of Cavgd28 and Cminss compared to IV Opdivo.
January 27, 2024
· 47 min read